Kura Oncology (KURA) Income from Continuing Operations (2010 - 2026)
Kura Oncology's (KURA) quarterly Income from Continuing Operations came in at 73333000.0 in Q1 2026, down 27.69% year-on-year from 101419406.55 in Q1 2025, and up 9.46% on a QoQ basis from 80999000.0 in Q4 2025.
Kura Oncology (KURA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has 8 years of Income from Continuing Operations data on file, last reported at 73333000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 27.69% year-over-year to 73333000.0 in Q1 2026; TTM through Mar 2026 was 294570000.0, a 3626.85% decrease from a year earlier, with the FY2025 full-year figure at 278666000.0, down 96996.17% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 73333000.0, up from 80999000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for KURA reached as high as 154766000.0 in Q4 2024 and fell as low as 80999000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 39111000.0 across 3 years, with a median of 57429000.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 15.96% in 2025 and fell as far as 152.34% in 2025.
- Year by year, Income from Continuing Operations stood at 154766000.0 in 2024, then sank by 152.34% to 80999000.0 in 2025, then increased by 9.46% to 73333000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 73333000.0 in Q1 2026, 80999000.0 in Q4 2025, and 74116000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Kura Oncology | 925.97 Mn | 925.97 Mn | 18.00 Mn | -73.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.33 Mn |
| Dec 31, 2025 | -81.00 Mn |
| Sep 30, 2025 | -74.12 Mn |
| Jun 30, 2025 | -66.12 Mn |
| Mar 31, 2025 | -57.43 Mn |
| Dec 31, 2024 | 154.77 Mn |
| Sep 30, 2024 | -54.40 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Mar 31, 2024 | -49.53 Mn |
| Dec 31, 2014 | -46,762.00 |
| Sep 30, 2014 | -6,428.00 |
| Jun 30, 2014 | -6,887.00 |
| Mar 31, 2014 | -5,766.00 |
| Dec 31, 2013 | -9,750.00 |
| Sep 30, 2013 | -6,139.00 |
| Jun 30, 2013 | -6,749.00 |
| Mar 31, 2013 | -5,973.00 |
| Dec 31, 2012 | -9,662.00 |
| Sep 30, 2012 | -6,013.00 |
| Jun 30, 2012 | -6,268.00 |